소화성 궤양 치료제 시장 규모, 점유율, 성장 분석 : 약제 유형별, 궤양 유형별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Peptic Ulcer Drugs Market size was valued at USD 4.93 Billion in 2024 and is poised to grow from USD 5.1 Billion in 2025 to USD 6.71 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The global market for peptic ulcer drugs is experiencing consistent growth, primarily influenced by the widespread prevalence of peptic ulcer disease, which impacts millions globally. Key drivers include an aging population and a rise in unhealthy lifestyle choices, such as smoking and excessive alcohol consumption. Moreover, innovations in medical technology and the development of new drug formulations are further propelling market expansion. However, the presence of generic alternatives and the rise of alternative treatment methods present challenges. Despite these hurdles, growing awareness around the necessity of early diagnosis and efficient treatment is anticipated to significantly enhance market dynamics, fostering continued advancements and adoption of peptic ulcer medications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peptic Ulcer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peptic Ulcer Drugs Market Segments Analysis

Global Peptic Ulcer Drugs Market is segmented by drug type, ulcer type, end user and region. Based on drug type, the market is segmented into proton pump inhibitors, H2 antagonists, antibiotics and others. Based on ulcer type, the market is segmented into gastric ulcer, duodenal ulcer and esophageal ulcer. Based on end user, the market is segmented into hospitals, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peptic Ulcer Drugs Market

A significant factor propelling the growth of the peptic ulcer drugs market is the rising incidence of peptic ulcers globally. These gastrointestinal disorders impact a vast number of individuals, resulting in an increased need for effective treatment solutions. Contributing elements, such as poor lifestyle choices, heightened stress levels, and the widespread use of non-steroidal anti-inflammatory drugs (NSAIDs), have been linked to the escalated occurrence of peptic ulcers. Consequently, this growing demand for effective medication not only highlights the importance of addressing this health issue but also fosters overall market expansion as healthcare providers seek to meet the needs of affected patients.

Restraints in the Peptic Ulcer Drugs Market

A key limitation facing the global peptic ulcer drugs market is the presence of various alternative treatment options. Many individuals turn to non-pharmacological methods, including lifestyle changes, dietary adjustments, and natural remedies, which are viewed as effective in managing peptic ulcers. This preference for alternatives can reduce the demand for conventional peptic ulcer medications. Additionally, concerns surrounding the potential side effects and health risks linked to prolonged use of these drugs may further deter patients and healthcare providers from relying solely on pharmaceuticals, ultimately affecting market trends and overall growth within the industry.

Market Trends of the Peptic Ulcer Drugs Market

A significant trend in the global peptic ulcer drugs market is the rising preference for proton pump inhibitors (PPIs) as the primary treatment choice. This shift is largely attributed to the superior efficacy and favorable safety profiles of PPIs in comparison to alternative therapies, as they significantly decrease stomach acid production, thereby offering prolonged symptom relief and aiding in ulcer healing. Furthermore, ongoing advancements in drug formulations have enhanced the bioavailability and compliance rates among patients, further solidifying the appeal of PPIs. The growing inclination toward this class of medications is poised to substantially influence demand dynamics within the peptic ulcer drugs market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peptic Ulcer Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Proton Pump Inhibitors
• H2 Antagonists
• Antibiotics
• Others

Global Peptic Ulcer Drugs Market Size by Ulcer Type & CAGR (2026-2033)

• Market Overview
• Gastric Ulcer
• Duodenal Ulcer
• Esophageal Ulcer

Global Peptic Ulcer Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Retail Pharmacies
• Online Pharmacies

Global Peptic Ulcer Drugs Market Size & CAGR (2026-2033)

• North America (Drug Type, Ulcer Type, End User)
  • US
  • Canada
• Europe (Drug Type, Ulcer Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Ulcer Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Ulcer Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Ulcer Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• AstraZeneca plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations